Alto Neuroscience (NYSE:ANRO) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $30.00 price objective on the stock.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a report on Monday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average target price of $31.17.

Alto Neuroscience Stock Down 7.3%

ANRO opened at $22.51 on Tuesday. The company has a market capitalization of $699.29 million, a P/E ratio of -10.32 and a beta of 2.52. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The firm’s fifty day moving average price is $18.11 and its two-hundred day moving average price is $13.35. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANRO. AlphaCore Capital LLC increased its holdings in shares of Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Alto Neuroscience in the second quarter valued at approximately $25,000. Wellington Management Group LLP acquired a new position in shares of Alto Neuroscience in the 4th quarter worth approximately $1,228,000. Armistice Capital LLC grew its position in Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in Alto Neuroscience during the 4th quarter worth approximately $619,000.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Alto secured approximately $120 million in a private placement (PIPE), strengthening near‑term cash runway to fund its clinical programs — a clear balance‑sheet positive for a clinical‑stage biotech. Read More.
• Positive Sentiment: Quarterly results: Alto reported ($0.45) EPS vs. consensus ($0.56), beating estimates and showing operating progress against expectations — a favorable signal for execution. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating and set a $30 price target, implying meaningful upside versus current levels and signaling continued analyst conviction in Alto’s pipeline. Read More.
• Neutral Sentiment: Wedbush raised its price target to $22 but kept a Neutral rating, effectively trimming the street’s short‑term upside view and providing mixed guidance to investors. Read More.
• Neutral Sentiment: Company released full‑year 2025 results and business highlights emphasizing pipeline progress and a stronger financial foundation entering 2026 — positive context but already priced against the financing and recent updates. Read More.
• Negative Sentiment: Potential dilution from the $120M PIPE — while the financing boosts cash, issuance of new securities can dilute existing shareholders and often weighs on the share price immediately after the announcement. Read More.
• Negative Sentiment: Market reaction: despite fundamentally positive items, mixed analyst positioning (Wedbush Neutral) plus dilution concerns have likely driven selling pressure and higher trading volume today. Read More.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.